Comparative bio‐availability and activity of properietary topical corticosteroid preparations: vasoconstrictor assays on thirty‐one ointments

No abstract is available for this paper.

• Publication year

  1975

• Venue

  British Journal of Dermatology

• Publication date

  1975-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2133.1975.tb02250.xPMID 1203181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative bio‐availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels

  1974cited by this paper
• Biostatistics -- An Introductory Text

  1965cited by this paper

• Skin permeation and penetration of mometasone furoate in the presence of emollients: An ex vivo evaluation of clinical application protocols

  2023cites this paper
• RANKJNG OF GLUCOCORTICOID CREAMS AND OINTMENTS

  2022cites this paper
• New Strategies for Improving Budesonide Skin Retention

  2021cites this paper
• The Impact of Clinical Application Protocols for Multiple Topical Products on Drug Delivery to the Skin

  2020cites this paper
• Topical Side Effects of Topical Corticosteroids

  2018cites this paper
• Principles of Topical Therapy

  2016cites this paper
• Research Techniques Made Simple: Drug Delivery Techniques, Part 2: Commonly Used Techniques to Assess Topical Drug Bioavailability.

  2016cites this paper
• Evaluation of Comparative Performance of Orally Inhaled Drug Products in View of the Classical Bioequivalence Paradigms: An Analysis of the Current Scientific and Regulatory Dilemmas of Inhaler Evaluation

  2014cites this paper
• Using In Vivo Bioavailability and/or In Vitro Gastrointestinal Bioaccessibility Testing to Adjust Human Exposure to Arsenic from Soil Ingestion

  2014cites this paper
• Brian Barry: Innovative Contributions to Transdermal and Topical Drug Delivery

  2013cites this paper
• Solute-Vehicle-Skin Interactions in Percutaneous Absorption: The Principles and the People

  2013cites this paper
• Clinical Use of Topical Corticosteroids

  2012cites this paper
• The ETS Family Transcription Factor ELK-1 Regulates Induction of the Cell Cycle-regulatory Gene p21Waf1/Cip1 and the BAX Gene in Sodium Arsenite-exposed Human Keratinocyte HaCaT Cells*

  2011cites this paper
• 73. Topical Therapy

  2010cites this paper
• ZJ The Human Skin Blanching Assay as an Indicator of TopicalCorticosteroid Bioavailability and Potency : An Update

  2007cites this paper
• Coordination of JNK1 and JNK2 Is Critical for GADD45α Induction and Its Mediated Cell Apoptosis in Arsenite Responses*

  2006cites this paper
• Correction: Cycooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells.

  2006cites this paper
• Percutaneous Absorption of Steroids: Determination of in vitro Permeability and Tissue Reservoir Characteristics in Human Skin Layers

  2006cites this paper
• Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells*

  2006cites this paper
• Cyclin D1 Induction through IκB Kinase β/Nuclear Factor-κB Pathway Is Responsible for Arsenite-Induced Increased Cell Cycle G1-S Phase Transition in Human Keratinocytes

  2005cites this paper
• Feasibility of Measuring the Bioavailability of Topical Betamethasone Dipropionate in Commercial Formulations Using Drug Content in Skin and a Skin Blanching Bioassay

  2004cites this paper
• Epidermal thinning: Evaluation of commercial corticosteroids

  2004cites this paper
• Factors Affecting the Formation of a Skin Reservoir for Topically Applied Solutes

  2003cites this paper
• Bioavailability and Bioequivalence of Dermatological Formulations

  2002cites this paper
• Dermatological And Transdermal Formulations

  2002cites this paper
• The Influence of Hydrocolloid Patch Composition on the Bioavailability of Triamcinolone Acetonide in Humans

  2000cites this paper
• Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling

  1999cites this paper
• Requirement of Erk, but Not JNK, for Arsenite-induced Cell Transformation*

  1999cites this paper
• Guidelines of care for the use of topical glucocorticosteroids. American Academy of Dermatology.

  1996cites this paper
• An In‐vitro Study of the Effect of Hydrocolloid Patch Occlusion on the Penetration of Triamcinolone Acetonide through Skin in Man

  1996cites this paper
• Topical corticosteroid formulations and water balance in the stratum corneum

  1995cites this paper
• The Human Skin Blanching Assay for Topical Corticosteroid Bioavailability Assessment

  1993cites this paper
• Topical Drug Bioavailability, Bioequivalence, and Penetration

  1993cites this paper
• Quantitative vasoconstrictor assay for topical corticosteroids: the puzzling case of fluocinolone acetonide.

  1993cites this paper
• Assessment of Topical Corticosteroid Bioavailability In Vivo and In Vitro

  1993cites this paper
• Ranking of topical glucocorticoids. Principles and results.

  1993cites this paper
• Topical betamethasone‐17‐valerate inhibits heat‐induced vasodilatation in man

  1993cites this paper
• NEW APPROACHES TO ASSESS TOPICAL CORTICOSTEROID BIOEQUIVALENCE: PHARMACOKINETIC EVALUATION

  1992cites this paper
• Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05 % betamethasone dipropionate bioavailability in humans

  1992cites this paper
• Blood Vessels and Immunoreactive Substance P‐Containing Nerve Fibers in Rat Skin Treated Topically with Clobetasol Propionate, a Corticosteroid

  1992cites this paper
• The human skin blanching assay for comparing topical corticosteroid availability

  1991cites this paper
• The humanskin blanchingassay for comparingtopical corticosteroid availability

  1991cites this paper
• Bioequivalence (bioavailability) of generic topical corticosteroids.

  1989cites this paper
• [The vasoconstriction test on normal skin. Technics and application].

  1988cites this paper
• Control of the bioavailability of a topical steroid; comparison of desonide creams 0·05% and 0·1% by vasoconstrictor studies and clinical trials

  1987cites this paper
• Intermittent application of clobetasol-17-propionate in psoriasis.

  1987cites this paper
• The Vasoconstrictor Test as a Model for Developing Topical Formulations

  1986cites this paper
• Activity and bioavailability of a new steroid (Timobesone acetate) in cream and ointment compared with Lidex and Dermovate creams and ointments and Betnovate cream

  1985cites this paper
• Assessment of topical corticoeroid preparations: the human skin blanching assay

  1984cites this paper
• Diskontinuierliche topische Corticoidtherapie

  1984cites this paper
• Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action

  1984cites this paper
• Optimization of bioavailability of topical steroids: penetration enhancers under occlusion.

  1984cites this paper
• An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations.

  1983cites this paper
• Percutaneous absorption: possibilities and problems

  1983cites this paper
• A comparison of the potencies of several diluted and undiluted corticosteroid preparations using the vasoconstrictor assay.

  1983cites this paper
• Intermittent maintenance therapy in chronic hand eczema with clobetasol propionate and flupredniden acetate.

  1983cites this paper
• Optimization of bioavailability of topical steroids: thermodynamic control.

  1982cites this paper
• The dilution of proprietary corticosteroid ointments – an attempt to evaluate relative clinical potencies

  1982cites this paper
• Steroids in dermatology.

  1982cites this paper
• [Release of flumethasone pivalate from oleogel and W/O emulsion bases in vitro].

  1982cites this paper
• Vasoconstrictor Assay of Proprietary Topical Corticosteroid Preparations in Japan

  1981cites this paper
• Topical Corticosteroids: Clinical Pharmacology and Therapeutic Use

  1980cites this paper
• Ranking of glucocorticoid creams and ointments.

  1980cites this paper
• [Comparative pharmacological activity of triamcinolone acetonide and of a new topical steroid: amcinonide, after percutaneous or oral administration (author's transl)].

  1980cites this paper
• The comparative efficacy of betamethasone dipropionate cream and ointment formulations in the treatment of psoriasis.

  1979cites this paper
• Bioavailability and activity of 0.1% amcinonide preparations: comparison with proprietary topical corticosteroid formulations of differing potencies

  1979cites this paper
• The effect of various corticosteroids on the release of β‐glucuronidase from human leukocytes challenged with zymosan

  1979cites this paper
• SKIN TUMORS OF THE LOWER EXTREMITIES

  1978cites this paper
• ACTIVITY AND BIOAVAILABILITY OF TOPICAL STEROIDS. IN VIVO / IN VITRO CORRELATIONS FOR THE VASOCONSTRICTOR TEST

  1978cites this paper
• Bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam.

  1977cites this paper
• Vasoconstrictor activities and bio‐availabilities of seven proprietary corticosteroid creams assessed using a non‐occluded multiple dosage regimen;clinical implications

  1977cites this paper
• Bioassays used in development of topical dosage forms.

  1976cites this paper
• Bioavailability of topical steroids.

  1976cites this paper
• Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.

  1976cites this paper
• Proprietary hydrocortisone creams

  1976cites this paper